These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24729718)

  • 21. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
    Cooper B; DeTora L; Stoddard J
    Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: systematic review and meta-analysis.
    Pellegrino P; Perrone V; Radice S; Capuano A; Clementi E
    Pharmacol Res; 2015 Feb; 92():31-9. PubMed ID: 25447792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence.
    Findlow J; Knuf M
    Future Microbiol; 2019 May; 14():563-580. PubMed ID: 31091978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age.
    Halperin SA; Baine Y; Domachowske JB; Aggarwal N; Simon M; Langley JM; McNeil SA; Friedland LR; Bianco V; Baccarini CI; Miller JM
    J Pediatric Infect Dis Soc; 2014 Mar; 3(1):33-42. PubMed ID: 24567843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.
    Rivera L; Chanthavanich P; Põder A; Suryakiran PV; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(27):3967-3975. PubMed ID: 29789243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
    Borja-Tabora C; Montalban C; Memish ZA; Van der Wielen M; Bianco V; Boutriau D; Miller J
    BMC Infect Dis; 2013 Mar; 13():116. PubMed ID: 23510357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
    Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.
    Perry CM
    Drugs; 2013 May; 73(7):703-13. PubMed ID: 23649970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies.
    Pina LM; Bassily E; Machmer A; Hou V; Reinhardt A
    Pediatr Infect Dis J; 2012 Nov; 31(11):1173-83. PubMed ID: 22814965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
    Deeks ED
    BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
    Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
    Ruiz-Palacios GM; Huang LM; Lin TY; Hernandez L; Guerrero ML; Villalobos AL; Van der Wielen M; Moreira M; Fissette L; Borys D; Miller JM
    Pediatr Infect Dis J; 2013 Jan; 32(1):62-71. PubMed ID: 23076383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
    Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.